These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25623883)

  • 1. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients.
    Inayat U Rahman ; Khan RU; Khalil Ur Rahman ; Bashir M
    Nutr J; 2015 Jan; 14():13. PubMed ID: 25623883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
    Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
    Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment.
    Inayat-ur-Rahman ; Malik SA; Bashir M; Khan R; Iqbal M
    Phytomedicine; 2009 May; 16(5):401-5. PubMed ID: 19362455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients.
    Fuangchan A; Sonthisombat P; Seubnukarn T; Chanouan R; Chotchaisuwat P; Sirigulsatien V; Ingkaninan K; Plianbangchang P; Haines ST
    J Ethnopharmacol; 2011 Mar; 134(2):422-8. PubMed ID: 21211558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice.
    Wang HY; Kan WC; Cheng TJ; Yu SH; Chang LH; Chuu JJ
    Food Chem Toxicol; 2014 Jul; 69():347-56. PubMed ID: 24751968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus.
    Cortez-Navarrete M; Martínez-Abundis E; Pérez-Rubio KG; González-Ortiz M; Méndez-Del Villar M
    J Med Food; 2018 Jul; 21(7):672-677. PubMed ID: 29431598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bitter melon (Momordica charantia): a review of efficacy and safety.
    Basch E; Gabardi S; Ulbricht C
    Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
    Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
    Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
    Koren S; Shemesh-Bar L; Tirosh A; Peleg RK; Berman S; Hamad RA; Vinker S; Golik A; Efrati S
    Diabetes Technol Ther; 2012 Jul; 14(7):561-7. PubMed ID: 22512265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
    Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
    Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management.
    Snee LS; Nerurkar VR; Dooley DA; Efird JT; Shovic AC; Nerurkar PV
    Nutr J; 2011 Jul; 10():78. PubMed ID: 21794176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bitter melon fruit extract enhances intracellular ATP production and insulin secretion from rat pancreatic
    Shimada T; Kato F; Dwijayanti DR; Nagata T; Kinoshita A; Okuyama T; Nishizawa M; Mukai E
    Br J Nutr; 2022 Feb; 127(3):377-383. PubMed ID: 33762029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.